Management of acute cardiac failure by intracoronary administration of levosimendan

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 3, 2011, Pages 246-253

  Caimmi, Philippe P ^a,b   Kapetanakis, Emmanouil I ^c   Beggino, Carla ^a,b   Molinari, Claudio ^b   Giustini, Giorgia ^a   Crosio, Enrico ^a,b   Reposo, Giovanni ^a   Micalizzi, Ezio ^a   Vacca, Giovanni ^b   Grossini, Elena ^b  

^a Cardiac Surgeon ^*  (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

cardiogenic shock; Heart failure; intracoronary administration; levosimendan

Indexed keywords

GLUCOSE; HEMOGLOBIN; LACTIC ACID; LEVOSIMENDAN;

ACUTE HEART FAILURE; ADULT; AGED; AORTA; ARTICLE; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CORONARY HEMODYNAMICS; ECHOCARDIOGRAPHY; FEMALE; GLUCOSE TRANSPORT; GRAFT PERFUSION; HEART INDEX; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE PERFUSION; HEART SURGERY; HUMAN; LACTATE BLOOD LEVEL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; FEMALE; HEART; HEART FAILURE; HEART RATE; HEMODYNAMICS; HUMANS; HYDRAZONES; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PYRIDAZINES; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, LEFT;

EID: 80052743532     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318220e491     Document Type: Article

References (31)

1. Papp Z, Csapo K, Pollesello P, et al. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev. 2005;23:71-98. (Pubitemid 40571678)
2. Mebazaa A, Barraud D, Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol. 2005;96:74G-79G (Pubitemid 41338077)
3. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev. 2007;12:149-156. (Pubitemid 46916961)
4. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27:1859-1866.
5. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during calcium sensitization with levosimendan: a non-invasive study with positron emission tomography and echocardiography in healthy volun-teers. Clin Pharmacol Ther. 1997;61:596-607. (Pubitemid 27261763)
6. Michaels AD, Mc Keown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111: 1504-1509. (Pubitemid 40470645)
7. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147. (Pubitemid 28527473)
8. Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet. 2007;46:535-552. (Pubitemid 47025356)
9. Grossini E, Molinari C, Caimmi PP, et al. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol. 2009;156:250-261.
10. Grossini E, Caimmi PP, Molinari C, et al. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig. J Cardiovasc Pharmacol. 2005;46:333-342. (Pubitemid 41262836)
11. Das B, Sarkar C. Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vascul Pharmacol. 2007;47:248-256. (Pubitemid 47470049)
12. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50: 257-263. (Pubitemid 47428972)
13. Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/ Rapp rats. Br J Pharmacol. 2007;150:851-861. (Pubitemid 46536624)
14. Caimmi PP, Molinari C, Uberti F, et al. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signalling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg. 2011;39:e59-e67.
15. Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment ofacute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur JHeart Fail. 2008;10:933-989.
16. Tassani P, Schad H, Heimisch W, et al. Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc Drugs Ther. 2002;16:435-441. (Pubitemid 36255743)
17. Caimmi PP, Grossini E, Molinari C, et al. Intracoronary infusion of levosimendan to treat post-pericardiotomy heart failure. Ann Thorac Surg. 2006;82:e33-e34. (Pubitemid 44584929)
18. Givertz MM, Andreou C, Conrad CH, et al. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequencyandrelaxation-frequencyrelationships. Circulation.2007;115:1218- 1224. (Pubitemid 46594765)
19. Dopfmer UR, Braun JP, Grosse J, et al. Temporary left ventricular assist and levosimendan for coronary artery spasm. Interact Cardiovasc Thorac Surg. 2005;4:316-318. (Pubitemid 41283747)
20. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br JAnaesth. 2009;102:198-204.
21. Guarracino F, Cariello C, Danella A, et al. Effect of levosimendan on ventriculo arterial coupling in patients with ischemic cardiomyopathy. Acta Anaesthesiol Scand. 2007;51:1217-1224. (Pubitemid 47389692)
22. Michaels AD, Mc Keown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111:1504-1509. (Pubitemid 40470645)
23. De Luca L, Proietti P, Celotto A, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J. 2005;150:563-568. (Pubitemid 41317630)
24. Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. JAm Coll Cardiol. 2004;43:2177-2182. (Pubitemid 38757582)
25. Jamali IN, Kersten JR, Pagel PS, et al. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg. 1997;85:23-29. (Pubitemid 27342270)
26. Pagel PS, Mc Gough MF, Hettrick DA, et al. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol. 1997;29:563-573. (Pubitemid 27276805)
27. Szilágyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guineapig. Eur J Pharmacol. 2004; 486:67-74. (Pubitemid 38130162)
28. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660-668. (Pubitemid 28224690)
29. Westaby S, Balacumaraswami L, Sayeed R. Maximizing survival potential in very high risk cardiac surgery. Heart Fail Clin. 2007;3:159-180. (Pubitemid 47069964)
30. Cheng JM, den Uil CA, Hoeks SE, et al. percutaneous left ventricular assist devices vs. intra-aortic balloon pump counter-pulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30:2102-2108.
31. Sylvin EA, Stern DR, Goldstein DJ. Mechanical support for post-cardiotomy cardiogenic shock: has progress been made? J Card Surg. 2010;25:442-454.